Inflammatory Pain is an indication for drug development with over 130 pipeline drugs currently active. According to GlobalData, preregistered drugs for Inflammatory Pain have a 72.73% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Inflammatory Pain compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Inflammatory Pain overview

Inflammatory pain stems from the body’s response to injury, infection, or autoimmune conditions, activating the immune system and releasing inflammatory molecules. This process triggers pain receptors, leading to localized discomfort, redness, swelling, and warmth. Conditions like arthritis, tendonitis, or infections often induce this type of pain. Inflammatory mediators, such as cytokines, prostaglandins, and histamine, sensitize nerve endings, heightening pain perception. Diagnosis involves assessing the underlying condition and inflammatory markers. Treatment focuses on addressing the cause, managing inflammation through medications (like NSAIDs or corticosteroids), physical therapy, and lifestyle changes, aiming to alleviate pain and reduce inflammation for improved function and comfort.

For a complete picture of PTSR and LoA scores for drugs in Inflammatory Pain, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.